Epstein-Barr Virus as a Possible Cause for Chronic Fatigue Syndrome - Tabular View

Tracking Information

First Received Date ^ICMJE

February 7, 2007

Last Updated Date

March 18, 2009

Start Date ^ICMJE

January 2007

Primary Completion Date

August 2008 (final data collection date for primary outcome measure)

Current Primary Outcome Measures ^ICMJE

Original Primary Outcome Measures ^ICMJE

Change History

Complete list of historical versions of study NCT00433355 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

Epstein-Barr Virus as a Possible Cause for Chronic Fatigue Syndrome

Official Title ^ICMJE

Studies on Epstein-Barr Virus as a Possible Etiological Agent for Chronic Fatigue Syndrome

Brief Summary

The purpose of this study is to understand what causes a continuing fatigue for a long time with a number of symptoms occurring at the same time (Chronic Fatigue Syndrome-CFS). Epstein Barr Virus is among the group of viruses that have been associated with a continuing fatigue for a long time with a number of symptoms occurring at the same time, but the cause is still unknown.

Detailed Description

Epstein-Barr virus (EBV) is the etiological agent for heterophile positive infectious mononucleosis (IM). It is also an oncogenic herpes virus associated with African Burkitt's lymphoma (BL),nasopharyngeal carcinoma (NPC) and AIDS-associated B-cell lymphomas. EBV is also among a group of viruses that have been associated with chronic fatigue syndrome (CFS), although the etiology of CFS still remains unknown.Findings may lead to hypothesize that EBV enzymes, such as the dUTPase, have the capacity to induce immune dysregulation of the T-cell and NK cell responses and that this immune dysregulation produces immunopathology that results in the symptoms that we call CFS.

Study Phase

Study Type ^ICMJE

Observational

Study Design ^ICMJE

Case Control, Prospective

Condition ^ICMJE

Chronic Fatigue Syndrome

Intervention ^ICMJE

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

Completion Date

October 2008

Primary Completion Date

August 2008 (final data collection date for primary outcome measure)

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Healthy adults for controls.
Adults with chronic fatigue syndrome.

Exclusion Criteria:

Individuals with significant medical illness in reference to immunosuppressant drug.

Note: We recruit participants in the Mississippi area who could come in our site to provide blood draw.

Gender

Both

Ages

18 Years and older

Accepts Healthy Volunteers

Yes

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

United States

Administrative Information

NCT ID ^ICMJE

NCT00433355

Responsible Party

Gailen D. Marshall, MD, PhD, The University of Mississippi Medical Center

Study ID Numbers ^ICMJE

2006-0265

Study Sponsor ^ICMJE

University of Mississippi Medical Center

Collaborators ^ICMJE

Ohio State University

Investigators ^ICMJE

Principal Investigator:

Gailen D Marshall, M.D., PhD

University of Mississippi Medical Center

Information Provided By

University of Mississippi Medical Center

Verification Date

March 2009

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP